News Flash

author

|
calendar

Apr 9, 2024

|
clock

3 minutes Read

|

General

We are thrilled to share some exciting news with all of you – Kyle Kappeler is back with us at Attentive Science! We couldn't be more thrilled to welcome Kyle back into the fold, and we would like to take a moment to convey our shared delight.


Dr. Kyle Kappeler has been an integral part of our Attentive Science family in the past, contributing immensely to our growth. And now, he has returned to bring his expertise back to our team. In his role as VP of Strategic Advisory and Client Relations, Kyle will be very attentive to your needs leveraging his skills, expertise, and passion to serve our clients worldwide as we expand our presence globally. Our aim as a company is to continue to provide you with quality, cost-effective in-vivo contract research solutions necessary to fortify your quest in developing cures and remedies.


After Kyle completed his NIEHS post-doctoral fellowship at The University of Arizona in the Department of Pharmacology and Toxicology, he proceeded into industry and gained over 15 years of toxicology experience in the contract research environment serving as Senior Toxicologist/Study Director, and later held the Director of Toxicology position at Attentive Science. Prior to re-joining Attentive Science, Dr. Kappeler was a nonclinical Consultant at Akkeri Associates and a Senior Consultant at Latham Biopharm Group providing technical oversight for preclinical study conduct and program management to ensure adherence to company defined regulatory timelines, and authoring of regulatory documents (pre-INDs, IND/NDA toxicological sections, Government proposals, and White Papers).


Kyle said “I’m most excited to be working with the boutique, flexible, experienced company once again. I think being small is an advantage in the current environment because we constantly re-evaluate our processes, receive constructive/meaningful input from our clients, which we use to make appropriate changes in a timely manner to avoid inefficiency. Lastly, I’m very grateful to have the opportunity to again work along-side Dr. Botchway (CEO) and the rest of the Attentive Science team as we meet the ever-growing needs of the non-clinical research industry”.


Dr. Kappeler has been responsible for the conduct of hundreds of preclinical studies in small and large test systems, which included early discovery (pharmacokinetic and formulation screening), non-GLP (maximum tolerated dose and repeat-dose range finder), GLP-compliant (subchronic/ chronic/ carcinogenicity), Highly Toxic Chemical Containment and BSL-3 Containment efficacy studies. Dr. Kappeler has published in peer-reviewed journals and presented posters/seminars at national/international conferences. Dr. Kappeler received his Ph.D. in Biomedical Sciences from the University of South Dakota and a B.S. in Biology from Mesa State College.


Call Kyle and us at 913 308 0700 or email him at kyle@attentivescience.com and let us help you with your planning, execution and reporting of your research programs 

About Attentive Science
Attentive Science is a non-clinical discovery and development company providing non-clinical contract research services to biotech and pharmaceutical, animal health, agrochemical and food industry. The Company focuses on supporting its clients’ discovery and development objectives to enable rapid acceleration of their products to market. Visit https://attentivescience.com for more information about the Company

Social Networks

Tags

Toxicology

NIEHS

Related Blogs